These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 31058718

  • 1. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, Phan BL, Pittman N, Dubinsky MC.
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F.
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
    Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Matuszczyk M, Kierkus J.
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):54-61. PubMed ID: 38477410
    [Abstract] [Full Text] [Related]

  • 6. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC.
    Inflamm Bowel Dis; 2021 Jul 27; 27(8):1210-1214. PubMed ID: 33125058
    [Abstract] [Full Text] [Related]

  • 7. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ, Borman ZA, Ji J, Dubinsky MC, Ungaro RC.
    Dig Dis Sci; 2022 Jun 27; 67(6):2480-2484. PubMed ID: 34021427
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A, Ben-Ya'acov A, Siterman M, Waterman M, Hirsh A, Schwartz D, Zittan E, Adler Y, Koslowsky B, Avni-Biron I, Chowers Y, Ron Y, Israeli E, Ungar B, Yanai H, Maharshak N, Ben-Horin S, Eliakim R, Dotan I, Goldin E, Kopylov U.
    United European Gastroenterol J; 2020 May 27; 8(4):418-424. PubMed ID: 32213026
    [Abstract] [Full Text] [Related]

  • 9. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN.
    Clin Gastroenterol Hepatol; 2021 Jul 27; 19(7):1366-1376.e2. PubMed ID: 32668338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG.
    Inflamm Bowel Dis; 2016 Jul 27; 22(7):1737-43. PubMed ID: 27306074
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M, UC-USK-GETAID Study Group.
    Aliment Pharmacol Ther; 2020 Jun 27; 51(11):1039-1046. PubMed ID: 32291786
    [Abstract] [Full Text] [Related]

  • 16. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A, Al Lehaibi LH, Alomar M, Aldhuwayan F, Alshouish S, Al-Ali AY, Almudhry Z, Almulhim A, Althagafi A, Aldosari S, AlAmeel T.
    Saudi J Gastroenterol; 2024 Sep 01; 30(5):324-334. PubMed ID: 39157885
    [Abstract] [Full Text] [Related]

  • 17. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, De Vos M, Van Moerkercke W, Rahier JF, Bossuyt P, Dutré J, Humblet E, Staessen D, Peeters H, Van Hootegem P, Louis E, Franchimont D, Baert F, Vermeire S, Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group].
    J Crohns Colitis; 2019 Oct 28; 13(11):1401-1409. PubMed ID: 30989232
    [Abstract] [Full Text] [Related]

  • 18. STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN.
    Pujol-Muncunill G, Navas-López VM, Ledder O, Cohen S, Lekar M, Turner D, Kolho KL, Levine A, Croft NM, Bronsky J, Shouval DS, Assa A, Harris R, Kiparissi F, Aloi M, Afzal NA, Tzivinikos C, Barrio J, Norden C, Vega MJB, Buderus S, de Valderrama AF, de Ridder L, García-Romero R, Medina E, Sánchez C, Velasco M, Vicente S, Wilson DC, Naik S, Hradsky O, Cococcioni L, Martin-de-Carpi J.
    Eur J Pediatr; 2024 Aug 28; 183(8):3253-3262. PubMed ID: 38700692
    [Abstract] [Full Text] [Related]

  • 19. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.
    Fumery M, Serrero M, Bouguen G, Amiot A, Altwegg R, Nachury M, Vuitton L, Treton X, Caillo L, Pereira B, Buisson A.
    J Crohns Colitis; 2024 Oct 15; 18(10):1615-1621. PubMed ID: 38742654
    [Abstract] [Full Text] [Related]

  • 20. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Meyer A, Fumery M, Peyrin-Biroulet L, Filippi J, Altwegg R, Bouhnik Y, Serrero M, Laharie D, Roblin X, Nachury M, Abitbol V, Cadiot G, Nancey S, Allez M, Gilletta C, Vuitton L, Savoye G, Nahon S, Bourrier A, Buisson A, Bouguen G, Bourreille A, Viennot S, Carbonnel F, Amiot A.
    Scand J Gastroenterol; 2022 Dec 15; 57(12):1454-1462. PubMed ID: 35819361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.